Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04548817 · ClinicalTrials.gov registry record
Neurocutaneous Melanocytosis Registry
A clinical trial of Cutaneous Melanocytic Neoplasm and Large Cutaneous Melanocytic Nevi, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 100
- Enrollment target
- 2
- Study locations
NCT04548817 is a study of Cutaneous Melanocytic Neoplasm and Large Cutaneous Melanocytic Nevi that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 100 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT04548817, a study of Cutaneous Melanocytic Neoplasm and Large Cutaneous Melanocytic Nevi, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will involve collecting information about the regular medical care you receive for large cutaneous melanocytic nevi (LCMN) or neurocutaneous melanocytosis (NCM).
Conditions Studied
Study Locations (2)
Massachusetts
- Boston Children's Hospital (Data Analysis Only) - Boston
New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-09-03 |
| Est. Completion | 2027-09-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04548817
The ClinicalTrials.gov registry entry for NCT04548817 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cutaneous Melanocytic Neoplasm appearing as the primary indexed condition, and to 0 interventions.
NCT04548817 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04548817 about?
NCT04548817 is a clinical study titled "Neurocutaneous Melanocytosis Registry". This study will involve collecting information about the regular medical care you receive for large cutaneous melanocytic nevi (LCMN) or neurocutaneous melanocytosis (NCM).
What is the current status of trial NCT04548817?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2020-09-03. Estimated completion is 2027-09-03.
What conditions does trial NCT04548817 study?
This clinical trial studies the following conditions: Cutaneous Melanocytic Neoplasm, Large Cutaneous Melanocytic Nevi, Neurocutaneous Melanocytosis.
Who is sponsoring clinical trial NCT04548817?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04548817 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Cutaneous Melanocytic Neoplasm
All registered trials for this condition
Large Cutaneous Melanocytic Nevi
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.